Alpa Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
ALPA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alpa Laboratories Limited has submitted its audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025, with an unmodified auditor opinion from C.H. Padliya & Co. On a standalone basis, FY25 revenue from operations rose modestly to ₹11,164.49 lakhs (FY24: ₹10,873.90 lakhs, +2.7%), but profit after tax fell to ₹1,677.77 lakhs from ₹1,967.94 lakhs (-14.7%), weighed down by weak Q4 performance. Consolidated FY25 PAT, however, improved to ₹1,950.31 lakhs from ₹1,677.65 lakhs (+16.3%). Q4 standalone revenue dropped sharply to ₹2,360.66 lakhs from ₹3,911.23 lakhs a year ago. The Board also approved the appointment of new Secretarial, Internal, and Cost Auditors.
Mixed bag for shareholders — full-year numbers are broadly stable, but the steep Q4 revenue and profit decline could weigh on short-term sentiment. The simultaneous change of three auditors is a governance point worth noting.